Listed by the USPTO as BASQUILL, SEAN M
Tech Center 1600 • Art Units: 1612 1613 1614 1617
This examiner grants 39% of resolved cases
BASQUILL, SEAN M works in Tech Center 1600 and Art Unit 1612. The profile records 1072 resolved cases, with a 38.8% allowance rate and a 21.7% interview lift. Interviews show a positive association that may help practitioners address a docket with a lower allowance outcome.
The median time to allowance is 1239 days. The leading companies are Ocular Therapeutix Inc., AbbVie Inc., and Perfuse Therapeutics Inc. The listed firms are COOLEY LLP, MYERS BIGEL, P.A., and BLANK ROME LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18737473 | ENHANCED PLANT GROWTH VIA PROCESSED PLANT CELL WALL MATERIAL | Non-Final OA | The Regents of the University of Michigan |
| 18535180 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | Non-Final OA | The Johns Hopkins University |
| 17772695 | SUPPOSITORY CAPSULE | Final Rejection | R.P. Scherer Technologies, LLC |
| 18840735 | COMPOSITIONS AND METHODS FOR LONG LASTING DISINFECTION WITH MIXED SOLVENT SYSTEMS | Non-Final OA | Specialty Operations France |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy38.8% of resolved applications examined by Sean M Basquill were allowed (1,072 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.
This examiner's interview lift is +21.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sean M Basquill took 1,239 days on average from filing to allowance.
Sean M Basquill examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
